[275 Pages Report] The global Actinic Keratosis Treatment Market was valued at US$ 5.0 Bn in 2021 and is expected to reach US$ 8.0 Bn by 2028, finds Future Market Insights (FMI) in a recent market survey.
Global demand for actinic keratosis treatment, majorly driven by that in the U.S. and European countries, continues to grow at a strong rate. Poised for revenues of over US$ 4 Bn by the end of 2019, the global actinic keratosis treatment market will exhibit an impressive CAGR of 7% during the forecast period (2019 – 2029).
The understanding about the nature of actinic keratosis and the potential risk of this condition progressing to squamous cell carcinoma (SCC) is improving, among patients as well as healthcare providers. Especially among the elderly, actinic keratosis remains one of the most commonly diagnosed dermatological condition that creates a continued need for efficacious treatments.
To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-3233
Who Is Winning?
The actinic keratosis treatment market report tracks the key market players, which includes GlaxoSmithKline Plc. Nestle SA, Novartis AG, Sun Pharmaceutical Ltd., Leo Pharma Inc. etc. Leading manufacturers in the actinic keratosis treatment market are focusing on acquisitions to enhance their product portfolio. For instance, in November 2015, Leo Pharma A/S completed the acquisition of dermatology business of Astellas Pharma. With this acquisition, the company expanded its dermatology product portfolio segment. Companies are also focusing on segment leadership. In February 2016, Cipher Pharmaceuticals Inc. launched Actikerall for the topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis to mark their leadership in topical product segment.
Combination therapies such as topical fluorouracil cryotherapy, PDT and imiquimod therapy, chemical peels, and 5-FU are generally the most prescribed therapies for actinic keratosis. Convenient administration, lower potential for irritation, and systemic absorption continue to underpin their high adoption rate. Development of drugs with increased efficacy and decreased side effects that can be used as combination therapy for actinic keratosis treatment is currently the focal point of global market leaders. Biofrontera AG commercially launched its product Ameluz (2016), used in combination with PDT for actinic keratosis treatment.
Development of minimally invasive drug-device combination therapies and fast track regulatory approval for pipeline drugs will be offering a completely new set of treatment options for actinic keratosis in the near future.
Key Takeaways – Actinic Keratosis Treatment Market Study
- Growing use of topical products as the first-line preference for actinic keratosis treatment is offering huge opportunities to market players to develop and launch new topical products for actinic keratosis treatment.
- Increasing collaboration activities by key market players of the actinic keratosis treatment market with other companies to broaden their products portfolio is anticipated to propel the actinic keratosis treatment market growth.
- For instance, in March 2017, Galderma SA (Nestle Skin Health Company) collaborated with Colorescience, to enhance its product portfolio for aesthetic treatment.
- Increasing product approvals of actinic keratosis treatment by regulatory bodies is expected to fuel the actinic keratosis treatment market growth.
- For instance, in March 2018, combination of Ameluz and daylight photodynamic therapy (PDT) by Biofrontera AG got approval from the European Union.
- The U.S. and Australia marking rise in incidence and prevalence of actinic keratosis will remain highly prominent markets for actinic keratosis treatment providers.
Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-3233
What Does the Report Cover?
Future Market Insights offers a unique perspective and actionable insights on actinic keratosis treatment market in its latest study, presenting historical demand assessment from 2014 – 2018 and projections from 2019 – 2029 on the basis of treatment category (topical treatment, procedural modality, photodynamic therapy and others), disease type (clinical AK and subclinical AK)and end-user (hospitals, laser therapy centers, private dermatology clinics, spas and rejuvenation centers, cancer treatment centers, homecare) in seven key regions.
Key Players :
- Sun Pharmaceutical Industries Ltd.
- Biofrontera
- Nestle SA
- Bausch Health Companies Inc.
- Novartis AG
- GlaxoSmithKline plc.
- Almirall, LLC
- LEO Pharma Inc.
- Cipher Pharmaceuticals Inc.
- Pierre Fabre Pharmaceuticals, Inc.
Request Discount @ https://www.futuremarketinsights.com/request-discount/rep-gb-3233
Actinic Keratosis Treatment Market By Category
By Treatment Type:
- Topical Treatment
- 5-fluorouracil Cream
- Diclofenac Gel
- Imiquimod Cream
- Ingenol mebutate Gel
- Procedural Modality
- Chemical Peels
- Cryotherapy
- Photodynamic Therapy
- Others
By Disease Type:
- Clinical AK
- Subclinical AK
By End User:
- Hospitals
- Private Dermatology Clinics
- Laser Therapy Centers
- Cancer Treatment Centers
- Spas and Rejuvenation Centers
- Homecare
More Trending Reports by Future Market Research :
[275 Pages Report] The global Actinic Keratosis Treatment Market was valued at US$ 5.0 Bn in 2021 and is expected to reach US$ 8.0 Bn by 2028, finds Future Market Insights (FMI) in a recent market survey.
Global demand for actinic keratosis treatment, majorly driven by that in the U.S. and European countries, continues to grow at a strong rate. Poised for revenues of over US$ 4 Bn by the end of 2019, the global actinic keratosis treatment market will exhibit an impressive CAGR of 7% during the forecast period (2019 – 2029).
The understanding about the nature of actinic keratosis and the potential risk of this condition progressing to squamous cell carcinoma (SCC) is improving, among patients as well as healthcare providers. Especially among the elderly, actinic keratosis remains one of the most commonly diagnosed dermatological condition that creates a continued need for efficacious treatments.
To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-3233
Who Is Winning?
The actinic keratosis treatment market report tracks the key market players, which includes GlaxoSmithKline Plc. Nestle SA, Novartis AG, Sun Pharmaceutical Ltd., Leo Pharma Inc. etc. Leading manufacturers in the actinic keratosis treatment market are focusing on acquisitions to enhance their product portfolio. For instance, in November 2015, Leo Pharma A/S completed the acquisition of dermatology business of Astellas Pharma. With this acquisition, the company expanded its dermatology product portfolio segment. Companies are also focusing on segment leadership. In February 2016, Cipher Pharmaceuticals Inc. launched Actikerall for the topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis to mark their leadership in topical product segment.
Combination therapies such as topical fluorouracil cryotherapy, PDT and imiquimod therapy, chemical peels, and 5-FU are generally the most prescribed therapies for actinic keratosis. Convenient administration, lower potential for irritation, and systemic absorption continue to underpin their high adoption rate. Development of drugs with increased efficacy and decreased side effects that can be used as combination therapy for actinic keratosis treatment is currently the focal point of global market leaders. Biofrontera AG commercially launched its product Ameluz (2016), used in combination with PDT for actinic keratosis treatment.
Development of minimally invasive drug-device combination therapies and fast track regulatory approval for pipeline drugs will be offering a completely new set of treatment options for actinic keratosis in the near future.
Key Takeaways – Actinic Keratosis Treatment Market Study
- Growing use of topical products as the first-line preference for actinic keratosis treatment is offering huge opportunities to market players to develop and launch new topical products for actinic keratosis treatment.
- Increasing collaboration activities by key market players of the actinic keratosis treatment market with other companies to broaden their products portfolio is anticipated to propel the actinic keratosis treatment market growth.
- For instance, in March 2017, Galderma SA (Nestle Skin Health Company) collaborated with Colorescience, to enhance its product portfolio for aesthetic treatment.
- Increasing product approvals of actinic keratosis treatment by regulatory bodies is expected to fuel the actinic keratosis treatment market growth.
- For instance, in March 2018, combination of Ameluz and daylight photodynamic therapy (PDT) by Biofrontera AG got approval from the European Union.
- The U.S. and Australia marking rise in incidence and prevalence of actinic keratosis will remain highly prominent markets for actinic keratosis treatment providers.
Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-3233
What Does the Report Cover?
Future Market Insights offers a unique perspective and actionable insights on actinic keratosis treatment market in its latest study, presenting historical demand assessment from 2014 – 2018 and projections from 2019 – 2029 on the basis of treatment category (topical treatment, procedural modality, photodynamic therapy and others), disease type (clinical AK and subclinical AK)and end-user (hospitals, laser therapy centers, private dermatology clinics, spas and rejuvenation centers, cancer treatment centers, homecare) in seven key regions.
Key Players :
- Sun Pharmaceutical Industries Ltd.
- Biofrontera
- Nestle SA
- Bausch Health Companies Inc.
- Novartis AG
- GlaxoSmithKline plc.
- Almirall, LLC
- LEO Pharma Inc.
- Cipher Pharmaceuticals Inc.
- Pierre Fabre Pharmaceuticals, Inc.
Request Discount @ https://www.futuremarketinsights.com/request-discount/rep-gb-3233
Actinic Keratosis Treatment Market By Category
By Treatment Type:
- Topical Treatment
- 5-fluorouracil Cream
- Diclofenac Gel
- Imiquimod Cream
- Ingenol mebutate Gel
- Procedural Modality
- Chemical Peels
- Cryotherapy
- Photodynamic Therapy
- Others
By Disease Type:
- Clinical AK
- Subclinical AK
By End User:
- Hospitals
- Private Dermatology Clinics
- Laser Therapy Centers
- Cancer Treatment Centers
- Spas and Rejuvenation Centers
- Homecare
More Trending Reports by Future Market Research :
Leukemia Therapeutics Treatment Market : During the forecast period, the leukemia therapeutics treatment market is expected to record a CAGR of 7.1 per cent to reach a valuation of US$ 17 Bn by 2024, from a valuation of US$ 13 Bn in 2020.
Non-invasive Surgical Wound Closure Market : The global non-invasive surgical wound closure market is estimated to be valued at US$ 2,192.3 billion in 2022. This market is expected to grow at a CAGR of 4.1% over the forecast period (2022-2032) to reach a market size of US$ 3,404.6 billion by 2032.
Mobile Cardiac Telemetry Systems Market : The global mobile cardiac telemetry systems market enjoys a valuation of US$ 825.3 Mn in 2021, and it is further projected to expand at a CAGR of 12.5% over the forecast years.
About FMI:
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs